Oncostatin M in Ulcerative Colitis Patients

Not Applicable

Not yet recruiting

• Conditions: Ulcerative Colitis
• Interventions: Diagnostic Test: Oncostatin M

• Registration Number: NCT05974332
• Lead Sponsor: Beni-Suef University

Brief Summary

Ulcerative colitis (UC) is a refractory disease characterized by symptoms such as diarrhea, bloody stools, and abdominal pain with repeated relapses and remissions.

Detailed Description

Evaluation of UC activity is important, and endoscopic evaluations of mucosal inflammation can facilitate subsequent prognostication. On the basis of these considerations, achievement of mucosal healing is important in inflammatory bowel disease (IBD), and evaluation of IBD using endoscopy is extremely important. However, endoscopic examinations are associated with problems such as physical burden to the patient, cost, and risk of complications.

Thus, to avoid the need for frequent endoscopy, noninvasive biomarkers that accurately reflect the endoscopic activity of UC have emerged, and fecal calprotectin (FC) and the fecal immunochemical occult blood test (FIT) are being widely used in clinical practice.

Study Timeline

• Status Verified: 2023-07
• Study First Submitted: 2023-07-26
• Study First Submitted QC: 2023-07-26
• Last Update Submitted: 2023-07-26
• Study Start: 2023-08-01
• Study First Posted: 2023-08-03
• Last Update Posted: 2023-08-03
• Primary Completion: 2024-02-28
• Study Completion: 2024-03-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 99

Inclusion Criteria

• All patients aged >18 years and <80 years, of both gender who diagnosed to have UC and given the consent for participation in the study

Exclusion Criteria

• 1- Any patient with systemic inflammation as Bronchial asthma. 2- History of cancer or tumor. 3- Autoimmune disease such as rheumatoid arthritis and systemic lupus erythematous

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ulcerative colitis Patients	Oncostatin M	45 Patients with UC. The diagnosis of UC will be based on endoscopic finding and histopathological finding
Control	Oncostatin M	45 apparently healthy subjects as controls who were not UC

Primary Outcome Measures

Name	Time	Method
Identify if oncostatin M is a good marker	6 months	Diagnosis of Ulcerative colitis and follow up